Evidence map›Paper›PMID 31110649›Full record

ArticleFacts, views & vision in ObGyn2018

HPV vaccination coverage in the federal state of Belgium according to regions and their impact.

Waa Tjalma, C Brasseur, G Top, N Ribesse, I Morales, P A Van Damme

Abstract readEditorial
In one paragraph

Article in Facts, views & vision in ObGyn, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Policy brief Belgian EBCP mirror group 'prevention' and 'early detection & screening' in cancer.Archives of public health = Archives belges de sante publique · 2024
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. HPV negative cervical cancers and primary HPV screening.Facts, views & vision in ObGyn · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Waa TjalmaMultidisciplinary Breast cancer clinic, Gynaecological Oncology Unit, Department of Obstetrics & Gynaecology, Antwerp University Hospital, University of Antwerp, Wilrijkstraat 10, 2650 Antwerpen, Belgium.
C BrasseurFrench Community, Immunization programme, Health department, Office of Birth and Childhood, Chaussée de Charleroi 95, B-1060 Bruxelles, Belgium.
G TopInfectious Disease Control and Vaccination, Flemish Agency for Care and Health, Ellipse Building, K. Albert II-laan 35, box 33, B-1030 Brussels, Belgium.
N RibesseFrench community, School Health Services support, Health department, Office of Birth and Childhood, Chaussée de Charleroi 95, B-1060 Bruxelles, Belgium.
I MoralesFrench Community, Immunization programme, Health department, Office of Birth and Childhood, Chaussée de Charleroi 95, B-1060 Bruxelles, Belgium.
P A Van DammeCentre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, Campus 3 Eiken, Universiteitsplein, 1, 2610 Antwerpen, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long-term results of the HPV vaccination programs in Australia and Scotland have shown a tremendous impact on the reduction of HPV infection rates and precancerous diseases. Both countries started mass vaccination ten years (Australia) and eight years (Scotland) ago and achieved a vaccination coverage of more than 80 %. Within 20 to 30 years a reduction in cervical cancer by more than 75 % is expected. Furthermore, there will be a reduction in other HPV related cancers like vaginal, vulva, perineal, anal and oropharyngeal cancers. In order to be successful, a high vaccination coverage is needed. In Belgium, the vaccination was introduced in 2010 in the Flemish community and in 2011 in the French community. In the first vaccinated cohorts the coverage in Flemish and French Communities was respectively 84% (2010) and 29% (2012-2013). The latest data suggest that the Flemish Community (Flanders Region) attained a coverage of 91 % while the French Community (Walloon Region) attained a coverage of around 36 %. The regional difference in coverage offers a real-life case. The worst-case scenario could end up with proportionally one half of country having more HPV related cancers than the other half. Currently efforts are performed to increase the coverage rates in both regions and consequently decreasing this difference. Additionally, the updated recommendations regarding the HPV vaccination by the Belgian NITAG (National Immunization Technical Advisory Group) stated that the HPV vaccination should be gender neutral. This could stimulate the vaccination program and increase the coverage. The coverage rate in Flanders is among the highest in the world and the rate in the French Community is increasing. Efforts should be continued in order to maintain trust and increase the coverage rate.

Indexed as

Belgiumcervical cancerdifferenceFlandersHPVvaccination coverageWalloon Region

Identifiers

PMID31110649
PMCPMC6516187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.